232 related articles for article (PubMed ID: 25820519)
1. Targeting thyroid hormone receptor beta in triple-negative breast cancer.
Gu G; Gelsomino L; Covington KR; Beyer AR; Wang J; Rechoum Y; Huffman K; Carstens R; Andò S; Fuqua SA
Breast Cancer Res Treat; 2015 Apr; 150(3):535-45. PubMed ID: 25820519
[TBL] [Abstract][Full Text] [Related]
2. Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells.
Tudoran O; Soritau O; Balacescu L; Visan S; Barbos O; Cojocneanu-Petric R; Balacescu O; Berindan-Neagoe I
Mol Cell Biochem; 2015 Nov; 409(1-2):163-76. PubMed ID: 26187676
[TBL] [Abstract][Full Text] [Related]
3. Filamin A (FLNA) modulates chemosensitivity to docetaxel in triple-negative breast cancer through the MAPK/ERK pathway.
Zhao P; Ma W; Hu Z; Zang L; Tian Z; Zhang K
Tumour Biol; 2016 Apr; 37(4):5107-15. PubMed ID: 26546439
[TBL] [Abstract][Full Text] [Related]
4. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
[TBL] [Abstract][Full Text] [Related]
5. The Thyroid Hormone Receptor-RUNX2 Axis: A Novel Tumor Suppressive Pathway in Breast Cancer.
Bolf EL; Gillis NE; Barnum MS; Beaudet CM; Yu GY; Tomczak JA; Stein JL; Lian JB; Stein GS; Carr FE
Horm Cancer; 2020 Feb; 11(1):34-41. PubMed ID: 31865591
[TBL] [Abstract][Full Text] [Related]
6. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
Seitz S; Rick FG; Schally AV; Treszl A; Hohla F; Szalontay L; Zarandi M; Ortmann O; Engel JB; Buchholz S
Oncol Rep; 2013 Jul; 30(1):413-8. PubMed ID: 23624870
[TBL] [Abstract][Full Text] [Related]
7. Activation of the RhoB signaling pathway by thyroid hormone receptor β in thyroid cancer cells.
Ichijo S; Furuya F; Shimura H; Hayashi Y; Takahashi K; Ohta K; Kobayashi T; Kitamura K
PLoS One; 2014; 9(12):e116252. PubMed ID: 25548921
[TBL] [Abstract][Full Text] [Related]
8. The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors.
Tormo E; Ballester S; Adam-Artigues A; Burgués O; Alonso E; Bermejo B; Menéndez S; Zazo S; Madoz-Gúrpide J; Rovira A; Albanell J; Rojo F; Lluch A; Eroles P
Sci Rep; 2019 Mar; 9(1):5316. PubMed ID: 30926829
[TBL] [Abstract][Full Text] [Related]
9. Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance.
Li S; Payne S; Wang F; Claus P; Su Z; Groth J; Geradts J; de Ridder G; Alvarez R; Marcom PK; Pizzo SV; Bachelder RE
Breast Cancer Res; 2015 Jul; 17(1):91. PubMed ID: 26141457
[TBL] [Abstract][Full Text] [Related]
10. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
[TBL] [Abstract][Full Text] [Related]
11. Common tumor-suppressive signaling of thyroid hormone receptor beta in breast and thyroid cancer cells.
Bolf EL; Gillis NE; Davidson CD; Cozzens LM; Kogut S; Tomczak JA; Frietze S; Carr FE
Mol Carcinog; 2021 Dec; 60(12):874-885. PubMed ID: 34534367
[TBL] [Abstract][Full Text] [Related]
12. miRNA expression patterns in chemoresistant breast cancer tissues.
Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
[TBL] [Abstract][Full Text] [Related]
13. The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling.
von Wahlde MK; Hülsewig C; Ruckert C; Götte M; Kiesel L; Bernemann C
Gynecol Endocrinol; 2015 Feb; 31(2):160-4. PubMed ID: 25356777
[TBL] [Abstract][Full Text] [Related]
14. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
Salaroglio IC; Gazzano E; Abdullrahman A; Mungo E; Castella B; Abd-Elrahman GEFA; Massaia M; Donadelli M; Rubinstein M; Riganti C; Kopecka J
J Exp Clin Cancer Res; 2018 Nov; 37(1):286. PubMed ID: 30482226
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
Kim EM; Mueller K; Gartner E; Boerner J
J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
[TBL] [Abstract][Full Text] [Related]
16. MiR-139-5p inhibits the biological function of breast cancer cells by targeting Notch1 and mediates chemosensitivity to docetaxel.
Zhang HD; Sun DW; Mao L; Zhang J; Jiang LH; Li J; Wu Y; Ji H; Chen W; Wang J; Ma R; Cao HX; Wu JZ; Tang JH
Biochem Biophys Res Commun; 2015 Oct; 465(4):702-13. PubMed ID: 26299922
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of cell-penetrant kinin B1 receptor antagonists in human triple-negative breast cancer cells.
Dubuc C; Savard M; Bovenzi V; Lessard A; Côté J; Neugebauer W; Geha S; Chemtob S; Gobeil F
J Cell Physiol; 2019 Mar; 234(3):2851-2865. PubMed ID: 30132865
[TBL] [Abstract][Full Text] [Related]
18. Integration of Ca
Abdoul-Azize S; Buquet C; Li H; Picquenot JM; Vannier JP
Oncogene; 2018 Sep; 37(36):4979-4993. PubMed ID: 29795329
[TBL] [Abstract][Full Text] [Related]
19. Regulation of beta-catenin by a novel nongenomic action of thyroid hormone beta receptor.
Guigon CJ; Zhao L; Lu C; Willingham MC; Cheng SY
Mol Cell Biol; 2008 Jul; 28(14):4598-608. PubMed ID: 18474620
[TBL] [Abstract][Full Text] [Related]
20. Enhanced cytotoxicity in triple-negative and estrogen receptor‑positive breast adenocarcinoma cells due to inhibition of the transient receptor potential melastatin-2 channel.
Koh DW; Powell DP; Blake SD; Hoffman JL; Hopkins MM; Feng X
Oncol Rep; 2015 Sep; 34(3):1589-98. PubMed ID: 26178079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
